Developer docs
API playgroundTry for free, no card

Search company profiles

Serpin Pharma

Full company profile

uuid0002h8p

Namestring
Serpin Pharma
Legal namestring
Serpin Pharma, Inc.
Company typeenum
Private
Founded yearint
2011
Descriptiontext

Serpin Pharma is a clinical-stage biopharmaceutical company developing SP16, a first-in-class synthetic anti-inflammatory peptide derived from residues 364-380 of alpha-1 antitrypsin (AAT). SP16 is approximately 300 times more potent than its natural counterpart and selectively activates the low-density lipoprotein receptor-related protein-1 (LRP1) receptor, resolving inflammation by clearing inflammatory triggers from cell surfaces, activating ERK/AKT cell-survival pathways, and suppressing NFkB-mediated pro-inflammatory signaling — restoring immune homeostasis rather than suppressing the immune response. The company is pursuing five therapeutic indications: acute kidney injury (AKI) in cardiac surgery patients with stage 2-3 CKD, acute myocardial infarction (AMI), chemotherapy-induced peripheral neuropathy (CIPN, including the SP16-3M variant in breast cancer), prurigo nodularis, and exploratory work in COVID-19 and HIV-related CNS inflammation. Additional formulations (intravenous, subcutaneous, topical) are tailored to each indication.

The company is headquartered in Manassas, Virginia, graduated from the Prince William Science Accelerator in 2022, and operates with 1-10 employees. Its IP estate comprises 13 granted patents (of 14 filed) covering composition of matter and use of the SERPIN peptide drug and analogs, with protection extending to 2041. Strategic partnerships include Dogwood Therapeutics (royalty-free global license for the IV SP16 formulation), Estée Lauder (cosmetics/skin-longevity application), Uniklinikum Erlangen (EASE-AKI Phase II), Sheba Medical Center (AMI Phase 2a), and the University of Virginia (CIPN Phase 1b and prior COVID-19 work). The company has not commercialized any product and has no product revenue; its operating capital to date has come primarily from non-dilutive grants (Virginia Catalyst $1.25M in 2021, BIRD Foundation $900K in 2024, NCI SBIR $2M in 2024, $2.5M NCI grant via Dogwood) and an early $400K round in 2017.

Short descriptiontext

Serpin Pharma is a clinical-stage biopharmaceutical company developing SP16, a synthetic LRP1-targeting peptide derived from alpha-1 antitrypsin that resolves inflammation across multiple indications including AKI, AMI, CIPN, and prurigo nodularis, with strategic applications in cosmetics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersManassas, United States
HQ citystring
Manassas
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
anti-inflammatory therapeutics, peptide drug development, clinical-stage biopharmaceutical, SERPIN protein therapeutics, LRP1 receptor agonists
Industry4 codes
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Anti-Inflammatory Therapeutics
Social media profiles1 record
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Serpin Pharma develops SP16, a first-in-class synthetic peptide therapeutic derived from alpha-1 antitrypsin (AAT) that selectively activates the LRP1 receptor to resolve inflammation and restore immune homeostasis. The company is advancing multiple clinical-stage programs targeting acute kidney injury, acute myocardial infarction, chemotherapy-induced peripheral neuropathy, and prurigo nodularis, supported by a 13-patent estate extending through 2041. All programs are based on a single molecular platform with different formulations (intravenous, subcutaneous, topical) tailored to each indication.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • In AMI, a single SP16 injection preserved heart function, reduced infarcts, and decreased biomarkers of cardiac injury in Phase 2a clinical trial
+3 more records
Product overview1 text field

Serpin Pharma is a clinical-stage biopharmaceutical company developing a single unified therapeutic platform centered on SP16, a first-in-class anti-inflammatory peptide derived from alpha-1 antitrypsin (AAT). SP16 is the core molecule with multiple clinical-stage indications: Acute Kidney Injury (AKI), Acute Myocardial Infarction (AMI), Chemotherapy-Induced Peripheral Neuropathy (CIPN), and Prurigo Nodularis. The company also developed SP16-3M variant for breast cancer patients. SP16 works by selectively activating the LRP1 receptor to restore immune homeostasis—removing inflammatory triggers, activating cell survival pathways (ERK/AKT), and deactivating pro-inflammatory NFkB pathways. Additional indications under investigation include COVID-19 and HIV-related inflammation. All programs are based on the same SP16 molecular platform with different formulations (intravenous, subcutaneous, topical) depending on indication.

Product and service9 records
1SP16 Peptide Therapeutic
2SP16 for Acute Kidney Injury (AKI)
3SP16 for Acute Myocardial Infarction (AMI)
4SP16 for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
5SP16 for Prurigo Nodularis
6SP16-3M for Breast Cancer CIPN Prevention
7SP16 for COVID-19 Inflammation
8SP16 for HIV-Induced Inflammation
9SP16 Anti-Inflammatory Peptide for Cosmetics and Skin Longevity
Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-09-01
Description

Dogwood Therapeutics secured a royalty-free global license for SP16's intravenous formulation from Serpin Pharma in September 2025. Dogwood advanced the drug candidate into clinical testing with FDA acceptance of IND application for SP16 for chemotherapy-induced pain and peripheral neuropathy.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-02-26
Description

Collaboration with Estée Lauder Companies Inc. announced in February 2025 to explore how anti-inflammatory peptides can be applied in cosmetics to improve skin health and longevity. This represents a commercial application of Serpin Pharma's technology in the cosmetics industry.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-17
Description

Partnership with Uniklinikum Erlangen in Germany for EASE-AKI Phase II clinical trial to assess efficacy and safety of SP16 in preventing acute kidney injury in at-risk patients with stage 2-3 chronic kidney disease undergoing cardiac surgery.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-24
Description

Collaboration with Sheba Medical Center (Ramat Gan, Israel), a global leader in innovative cardiology care, for randomized controlled Phase 2a clinical trial targeting acute myocardial infarction (AMI) patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Phase 1b clinical trial for SP16 expected to begin patient enrollment at the University of Virginia. Dr. Michael Yun Shim serves as Principal Investigator for COVID-19 clinical investigation.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Clinical-stage biotech developing peptide therapeutics (DM199) for acute kidney injury and other inflammatory conditions. Directly comparable as a peptide therapeutic company focused on AKI with Phase 2-stage development.

TypeDirect peer
Description

Clinical-stage biopharmaceutical company developing therapeutics for fibrosis and inflammation, with multiple indications in Phase 2 development. Comparable as a clinical-stage inflammation-focused biotech with platform technology approach.

TypeDirect peer
Description

Holds royalty-free global license for SP16 IV formulation and is advancing Halneuron for chemotherapy-induced neuropathic pain. Direct peer given shared SP16 technology and overlapping CIPN indication.

TypeDirect peer
Description

Clinical-stage biotech developing protein therapeutics targeting TGF-β superfamily for inflammation and hematological diseases. Comparable clinical-stage company with engineered protein therapeutics and multi-indication platform approach.

5Athersys
TypeEmerging player
Description

Clinical-stage company developing MultiStem cell therapy for inflammatory and immune-mediated conditions across multiple indications. Comparable multi-indication platform approach to inflammatory diseases though different modality (cell therapy vs. peptide).

TypeBroad incumbent
Description

Specialty biopharmaceutical company with kidney disease and rare disease focus including therapies for kidney conditions. Comparable kidney disease therapeutic focus though broader portfolio and more advanced commercial stage.

TypeBroad incumbent
Description

Clinical-stage regenerative medicine company developing cellular therapies for inflammatory and immune-mediated diseases. Comparable clinical-stage inflammation therapeutics with multi-indication platform, though using cell therapy modality.

8ChemoCentryx
TypeBroad incumbent
Description

Was a clinical-stage inflammation biotech acquired by Amgen for $3.7B in 2022, focused on chemoattractant receptor therapeutics. Comparable clinical-stage inflammation therapeutics company, though now part of larger pharma following acquisition.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Serpin Pharma

Anti-Inflammatory Therapeuticsserpinpharma.com

Serpin Pharma is a clinical-stage biopharmaceutical company developing SP16, a synthetic LRP1-targeting peptide derived from alpha-1 antitrypsin that resolves inflammation across multiple indications including AKI, AMI, CIPN, and prurigo nodularis, with strategic applications in cosmetics.

What Serpin Pharma does

Serpin Pharma is a clinical-stage biopharmaceutical company developing SP16, a first-in-class synthetic anti-inflammatory peptide derived from residues 364-380 of alpha-1 antitrypsin (AAT). SP16 is approximately 300 times more potent than its natural counterpart and selectively activates the low-density lipoprotein receptor-related protein-1 (LRP1) receptor, resolving inflammation by clearing inflammatory triggers from cell surfaces, activating ERK/AKT cell-survival pathways, and suppressing NFkB-mediated pro-inflammatory signaling — restoring immune homeostasis rather than suppressing the immune response. The company is pursuing five therapeutic indications: acute kidney injury (AKI) in cardiac surgery patients with stage 2-3 CKD, acute myocardial infarction (AMI), chemotherapy-induced peripheral neuropathy (CIPN, including the SP16-3M variant in breast cancer), prurigo nodularis, and exploratory work in COVID-19 and HIV-related CNS inflammation. Additional formulations (intravenous, subcutaneous, topical) are tailored to each indication.

The company is headquartered in Manassas, Virginia, graduated from the Prince William Science Accelerator in 2022, and operates with 1-10 employees. Its IP estate comprises 13 granted patents (of 14 filed) covering composition of matter and use of the SERPIN peptide drug and analogs, with protection extending to 2041. Strategic partnerships include Dogwood Therapeutics (royalty-free global license for the IV SP16 formulation), Estée Lauder (cosmetics/skin-longevity application), Uniklinikum Erlangen (EASE-AKI Phase II), Sheba Medical Center (AMI Phase 2a), and the University of Virginia (CIPN Phase 1b and prior COVID-19 work). The company has not commercialized any product and has no product revenue; its operating capital to date has come primarily from non-dilutive grants (Virginia Catalyst $1.25M in 2021, BIRD Foundation $900K in 2024, NCI SBIR $2M in 2024, $2.5M NCI grant via Dogwood) and an early $400K round in 2017.

Serpin Pharma firmographics

Firmographics
Name
Serpin Pharma
Legal name
Serpin Pharma, Inc.
Website
https://serpinpharma.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
1–10 employees
Short description
Serpin Pharma is a clinical-stage biopharmaceutical company developing SP16, a synthetic LRP1-targeting peptide derived from alpha-1 antitrypsin that resolves inflammation across multiple indications including AKI, AMI, CIPN, and prurigo nodularis, with strategic applications in cosmetics.
Ownership category
akta.pro rank

Serpin Pharma industry classification

Industry
Product category
Anti-Inflammatory Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAJ
Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds)
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIAAAM
Nephrology & Urology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals

Keywords

  • Anti-inflammatory therapeutics
  • Peptide drug development
  • Clinical-stage biopharmaceutical
  • SERPIN protein therapeutics
  • LRP1 receptor agonists

Where Serpin Pharma is headquartered

Location

Headquarters

HQ city
Manassas
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Serpin Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Marketing channels4 records

Serpin Pharma product offering

Product offering

Core offering

Serpin Pharma develops SP16, a first-in-class synthetic peptide therapeutic derived from alpha-1 antitrypsin (AAT) that selectively activates the LRP1 receptor to resolve inflammation and restore immune homeostasis. The company is advancing multiple clinical-stage programs targeting acute kidney injury, acute myocardial infarction, chemotherapy-induced peripheral neuropathy, and prurigo nodularis, supported by a 13-patent estate extending through 2041. All programs are based on a single molecular platform with different formulations (intravenous, subcutaneous, topical) tailored to each indication.

Product overview

Serpin Pharma is a clinical-stage biopharmaceutical company developing a single unified therapeutic platform centered on SP16, a first-in-class anti-inflammatory peptide derived from alpha-1 antitrypsin (AAT). SP16 is the core molecule with multiple clinical-stage indications: Acute Kidney Injury (AKI), Acute Myocardial Infarction (AMI), Chemotherapy-Induced Peripheral Neuropathy (CIPN), and Prurigo Nodularis. The company also developed SP16-3M variant for breast cancer patients. SP16 works by selectively activating the LRP1 receptor to restore immune homeostasis—removing inflammatory triggers, activating cell survival pathways (ERK/AKT), and deactivating pro-inflammatory NFkB pathways. Additional indications under investigation include COVID-19 and HIV-related inflammation. All programs are based on the same SP16 molecular platform with different formulations (intravenous, subcutaneous, topical) depending on indication.

Differentiator

Problem solved

Functional benefit

Products and services

  • SP16 Peptide Therapeutic
  • SP16 for Acute Kidney Injury (AKI)
  • SP16 for Acute Myocardial Infarction (AMI)
  • SP16 for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  • SP16 for Prurigo Nodularis
  • SP16-3M for Breast Cancer CIPN Prevention
  • SP16 for COVID-19 Inflammation
  • SP16 for HIV-Induced Inflammation
  • SP16 Anti-Inflammatory Peptide for Cosmetics and Skin Longevity

Quantifiable outcome

  • In AMI, a single SP16 injection preserved heart function, reduced infarcts, and decreased biomarkers of cardiac injury in Phase 2a clinical trial
  • +3 more outcomes

Companies that use Serpin Pharma

Customer profile

Segments5 records

Ideal customer profiles2 records

Serpin Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Serpin Pharma partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and major.

  • Dogwood TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 1 September 2025Dogwood Therapeutics secured a royalty-free global license for SP16's intravenous formulation from Serpin Pharma in September 2025. Dogwood advanced the drug candidate into clinical testing with FDA acceptance of IND application for SP16 for chemotherapy-induced pain and peripheral neuropathy.
  • Estée Lauder CompaniescoreStrategic or Co-development Partner · 26 February 2025Collaboration with Estée Lauder Companies Inc. announced in February 2025 to explore how anti-inflammatory peptides can be applied in cosmetics to improve skin health and longevity. This represents a commercial application of Serpin Pharma's technology in the cosmetics industry.
  • Uniklinikum ErlangencoreStrategic or Co-development Partner · 17 September 2024Partnership with Uniklinikum Erlangen in Germany for EASE-AKI Phase II clinical trial to assess efficacy and safety of SP16 in preventing acute kidney injury in at-risk patients with stage 2-3 chronic kidney disease undergoing cardiac surgery.
  • Sheba Medical CentermajorStrategic or Co-development Partner · 24 January 2024Collaboration with Sheba Medical Center (Ramat Gan, Israel), a global leader in innovative cardiology care, for randomized controlled Phase 2a clinical trial targeting acute myocardial infarction (AMI) patients.
  • University of VirginiacoreStrategic or Co-development PartnerPhase 1b clinical trial for SP16 expected to begin patient enrollment at the University of Virginia. Dr. Michael Yun Shim serves as Principal Investigator for COVID-19 clinical investigation.

Scale indicators9 records

Recent moves7 records

Expansion highlights5 records

Serpin Pharma competitors and assessment

Company assessment

Direct peers

  • DiaMedica Therapeutics: Clinical-stage biotech developing peptide therapeutics (DM199) for acute kidney injury and other inflammatory conditions. Directly comparable as a peptide therapeutic company focused on AKI with Phase 2-stage development.
  • Pliant Therapeutics: Clinical-stage biopharmaceutical company developing therapeutics for fibrosis and inflammation, with multiple indications in Phase 2 development. Comparable as a clinical-stage inflammation-focused biotech with platform technology approach.
  • Dogwood Therapeutics: Holds royalty-free global license for SP16 IV formulation and is advancing Halneuron for chemotherapy-induced neuropathic pain. Direct peer given shared SP16 technology and overlapping CIPN indication.
  • Keros Therapeutics: Clinical-stage biotech developing protein therapeutics targeting TGF-β superfamily for inflammation and hematological diseases. Comparable clinical-stage company with engineered protein therapeutics and multi-indication platform approach.

Emerging players

  • Athersys: Clinical-stage company developing MultiStem cell therapy for inflammatory and immune-mediated conditions across multiple indications. Comparable multi-indication platform approach to inflammatory diseases though different modality (cell therapy vs. peptide).

Broad incumbents

  • Travere Therapeutics: Specialty biopharmaceutical company with kidney disease and rare disease focus including therapies for kidney conditions. Comparable kidney disease therapeutic focus though broader portfolio and more advanced commercial stage.
  • Mesoblast: Clinical-stage regenerative medicine company developing cellular therapies for inflammatory and immune-mediated diseases. Comparable clinical-stage inflammation therapeutics with multi-indication platform, though using cell therapy modality.
  • ChemoCentryx: Was a clinical-stage inflammation biotech acquired by Amgen for $3.7B in 2022, focused on chemoattractant receptor therapeutics. Comparable clinical-stage inflammation therapeutics company, though now part of larger pharma following acquisition.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

Serpin Pharma social profiles

Digital presence

Serpin Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Serpin Pharma leadership team

Management profile

Number of profiles

Profiles13 records

Serpin Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Serpin Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Serpin Pharma

What does Serpin Pharma do?

Serpin Pharma develops SP16, a first-in-class synthetic peptide therapeutic derived from alpha-1 antitrypsin (AAT) that selectively activates the LRP1 receptor to resolve inflammation and restore immune homeostasis. The company is advancing multiple clinical-stage programs targeting acute kidney injury, acute myocardial infarction, chemotherapy-induced peripheral neuropathy, and prurigo nodularis, supported by a 13-patent estate extending through 2041. All programs are based on a single molecular platform with different formulations (intravenous, subcutaneous, topical) tailored to each indication.

Is Serpin Pharma a public or private company?

Serpin Pharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Serpin Pharma founded?

Serpin Pharma was founded in 2011. It employs 1 to 10 people.

Where is Serpin Pharma based?

Serpin Pharma is headquartered in Manassas, United States, in the North America region.

Who are Serpin Pharma's main competitors?

Direct peers on record are DiaMedica Therapeutics, Pliant Therapeutics, Dogwood Therapeutics and Keros Therapeutics. Athersys is listed as an emerging player. Broad incumbents are Travere Therapeutics, Mesoblast and ChemoCentryx.

Does Serpin Pharma have an API?

No public API is recorded for Serpin Pharma.

What industry is Serpin Pharma in?

Serpin Pharma's product category is Anti-Inflammatory Therapeutics. Its primary akta.pro industry code is HLAAAAAH, Therapeutic Peptides & Protein/Peptide Biologics, with a secondary code of HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireThe Estée Lauder Companies Partners with Serpin Pharma, Inc to Develop Breakthrough Skin Care Ingredients to Advance LongevityThe Estée Lauder Companies announced a partnership with Serpin Pharma to explore anti-inflammatory research for skin care longevity. Serpin Pharma's technology, 300 times more potent than natural Alfa-1 Antitrypsin, aims to reduce skin aging and irritation. Scientific studies are underway to demonstrate cosmetic applications.Stock TitanDogwood FDA accepts SP16 IND for chemo pain trialDogwood Therapeutics announced FDA acceptance of its Investigational New Drug application for SP16, an intravenously administered candidate for treating chemotherapy-induced pain and peripheral neuropathy. The Phase 1b clinical trial will be fully funded by a $2.5 million National Cancer Institute grant, with patient enrollment expected to begin in mid-2026 at the University of Virginia under partnership with Serpin Pharma, which holds the IND and serves as regulatory sponsor. Dogwood licensed the global rights to develop and commercialize SP16 from Serpin Pharma in September 2025.EIN PresswireSerpin Pharma Receives FDA Clearance of IND Application for SP16 for Chemotherapy-Induced Peripheral NeuropathySerpin Pharma received FDA clearance for its IND application for SP16, a peptide therapy for chemotherapy-induced peripheral neuropathy. The company plans to initiate a Phase 1b trial evaluating safety and pharmacokinetics. SP16 targets LRP1 to modulate inflammation and nerve repair.EIN PresswireSerpin Pharma, Inc. Announces Approval to Initiate EASE AKI Phase II Clinical Trial in GermanySerpin Pharma received unconditional approval from German regulators to initiate its Phase II EASE-AKI clinical trial evaluating the anti-inflammatory peptide SP16 in 120 patients undergoing heart bypass surgery. The trial will assess whether perioperative administration of SP16 can reduce the incidence and severity of acute kidney injury, a condition with no currently approved pharmacologic therapy. The study is being conducted in collaboration with principal investigators from University Hospital Erlangen.Investing.comDogwood reports positive interim results for pain treatment By Investing.comDogwood Therapeutics announced positive interim results from its Phase 2b clinical trial of Halneuron, an experimental non-opioid pain treatment for chemotherapy-induced neuropathic pain, with an independent statistical review committee finding separation from placebo in pain improvement among 97 patients who completed treatment. The company, currently valued at $186 million with a stock surge of 175% over the past year, expects top-line results in Q3 2026 and the treatment has received FDA fast track designation. H.C. Wainwright recently raised its price target to $12 maintaining a Buy rating, and the company also secured a royalty-free global license for Serpin Pharma's SP16 for chemotherapy-induced peripheral neuropathy.openPR.comAnti-Aging Market (CAGR 7.37%): Driving Growth Through Skincare Innovation & Rising Consumer Wellness DemandCustom Market Insights released a market analysis projecting the global anti-aging market to grow from USD 79.8 billion in 2025 to USD 162.5 billion by 2034, representing a CAGR of 7.37% over the forecast period. The report attributes growth to rising consumer demand for skincare solutions, technological advancements in AI-enabled diagnostics, increasing adoption of medical aesthetics, and expanding disposable incomes in Asia-Pacific and Latin America. In February 2025, Estée Lauder Companies entered into a collaboration with Serpin Pharma to develop innovative skincare ingredients focused on longevity.Ingredients-InsightEstée Lauder partners with Serpin Pharma for skin care ingredientsEstée Lauder has entered into a partnership with Serpin Pharma to source ingredients for its skin care products. This collaboration aims to integrate Serpin Pharma's specialized ingredients into Estée Lauder's beauty portfolio.BeautypackagingELC Partners with Serpin Pharma for Advanced Longevity Skincare IngredientsThe Estée Lauder Companies partnered with Serpin Pharma to apply anti-inflammatory research in cosmetics for skincare longevity benefits. Serpin Pharma's proprietary technology targets SERPIN proteins to mitigate inflammation and enhance cell resiliency. Scientific studies are underway to demonstrate the technology's application in cosmetic products.Investing.comELC partners with Serpin Pharma for skin care innovation By Investing.comThe Estée Lauder Companies announced an exclusive partnership with Serpin Pharma to develop skin care products using anti-inflammatory technology. The collaboration aims to create solutions for skin irritation, aging, and sensitivity, leveraging Serpin Pharma's research on SERPIN proteins. The initiative is part of ELC's Beauty Reimagined strategy.